Vafseo
Vafseo (vadadustat) was approved for the following therapeutic use:
Vafseo is indicated for the treatment of anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
Vadadustat is an inhibitor of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH), a group of enzymes that degrade a subunit of hypoxia-inducible factor (HIF) in the presence of oxygen under normal physiological conditions. HIF mediates tissue adaption to low oxygen environments through transcriptional regulation of gene expression. Decreased HIF-PH activity with vadadustat leads to increased cellular levels of HIF thereby stimulating endogenous 13 erythropoietin production, increasing iron mobilization and red blood cell production, resulting in a gradual rate of rise in haemoglobin.